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Abstract 
The in vitro antioxidant and growth inhibitory activity of extracts obtained from two 
Portuguese wild mushrooms (Clitocybe alexandri and Lepista inversa) was studied in 
human tumour cell lines. The extracts were phenolic (methanolic and ethanolic) and 
polysaccharidic (boiling water). The antioxidant activity assays included evaluation of 
radical scavenging capacity, reducing power and inhibition of lipid peroxidation 
measured in liposome solutions. Extract-induced cell growth inhibition was measured in 
four different tumour cell lines (lung, breast, colon and gastric cancer) using the SRB 
assay. The polysaccharidic extract of Lepista inversa was the most potent as antioxidant 
(EC50 < 1.8 ± 0.1 mg/ml), while the phenolic ethanolic extract of Clitocybe alexandri 
was the most potent as inhibitor of growth of the studied cancer cell lines (GI50 < 26.0 ± 
1.3 µg/ml). Together, these activities indicate that these mushrooms are promising 
sources of bioactive compounds.   
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1. Introduction  
Edible mushrooms have been widely used as human food for centuries and have been 
appreciated for texture and flavour as well as some medicinal and tonic attributes. 
However, the awareness of mushrooms as being a healthy food and as an important 
source of biological active substances with medicinal value has only recently emerged. 
Various activities of mushrooms have been studied which include antibacterial, 
antifungal, antioxidant, antiviral, antitumour, cytostatic, immunosuppressive, 
antiallergic, antiatherogenic hypoglycemic, anti-inflammatory and hepatoprotective 
activities (Lindequist et al., 2005).  
Many studies have concluded that edible mushrooms possess potent antioxidants. The 
antioxidants found in mushrooms are mainly phenolic compounds (phenolic acids and 
flavonoids), followed by tocopherols, ascorbic acid and carotenoids. These molecules 
were quantified in many different species mainly from Finland, India, Korea, Poland, 
Portugal, Taiwan and Turkey (Ferreira et al., 2009). Other phytochemicals have been 
isolated from medicinal mushrooms and three of these, which are cytostatic 
polysaccharide drugs, have been developed from mushrooms in Japan. These are 
“Krestin” (PSK), from the cultured mycelium of Kawaratake (Trametes versicolor), 
“Lentinan” from the fruiting bodies of Shiitake (Lentinus edodes) and “Schizophyllan” 
(Sonifilan) from the culture fluid of Suehirotake (Schizophyllum commune) (Mizuno, 
1993). Lentinan and Schizophyllan are pure β-glucans, whereas PSK is a protein bound 
polysaccharide (Larone, 2002). The biological activity of these three products is related 
to their immunomodulating properties, which enhance the body’s defences against 
various forms of infectious disease. These immunopotentiators (or immunoinitiators) 
are also referred as “biological response modifiers” (Zjawiony, 2004; Zaidman et al., 
2005). 
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The most common causes of cancer related deaths in Europe in 2006 were lung, breast, 
colorectal and prostate cancer (Ferlay et al., 2007; Karim-Kos et al., 2008). 
Furthermore, evidence-based studies suggest there is a relationship between the 
physiopathology of several chronic diseases (e.g. cancer) and oxidative stress. 
Therefore, the use of foods with antioxidant capacity as phytochemical protectors may 
be relevant for the prevention of oxidative stress related diseases (Finco et al., 2009). 
Moreover, there is a need to discover new molecules that are able to effectively reduce 
tumour cell growth. In the present work we studied whether two Portuguese mushroom 
species possess antioxidant activities and/or tumour cell growth inhibition properties.  
 
2. Materials and methods 
 
2.1. Mushroom species 
Samples of Clitocybe alexandri (Gillet) Konrad (Tricholomataceae) and Lepista inversa 
(Scop.: Fr.) Pat. (Tricholomataceae) were collected under Quercus pyrenaica Willd. and 
mixed stands of Quercus sp. and Pinus sylvestris Ait., in Bragança (Northeast Portugal), 
in autumn 2008. Taxonomic identification of sporocarps was made according to several 
authors (Marchand, 1971-1986; Breitenbach and Kränzlin, 1984-2000; Bon, 1988; 
Courtecuisse, 1999; Courtecuisse and Duhem, 2005; online keys: 
http://www.mycokey.com/), and representative voucher specimens were deposited at the 
herbarium of Escola Superior Agrária of Instituto Politécnico de Bragança. Both species 
are saprotrophic and edible. All the samples were lyophilised (Ly-8-FM-ULE, Snijders) 
and reduced to a fine dried powder (20 mesh). 
 
2.2. Standards and reagents 
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Methanol and ethanol were of analytical grade purity and supplied by Pronalab (Lisbon, 
Portugal). Water was treated in a Milli-Q water purification system (TGI Pure Water 
Systems, USA). Fetal bovine serum (FBS) was obtained from Invitrogen (Paisley, UK) 
and RPMI-1640 medium from Lonza (Basel, Switzerland). Dimethylsulfoxide (DMSO), 
sulforhodamine B (SRB) and all other reagents were purchased from Sigma Chemical 
Co. (St. Louis, MO, USA), unless otherwise stated.  
 
2.3. Preparation of phenolic (methanolic and ethanolic) and polysaccharidic (boiling 
water) extracts  
For methanolic extracts, each mushroom lyophilized sample (~2 g) was extracted with 
methanol (50 ml) mixture at -20 °C for 6 h. The extract was sonicated for 15 min, 
centrifuged at 4000 × g for 10 min, and filtered through Whatman nº 4 paper. The 
residue was then extracted with three additional 50 ml portions of methanol. The 
combined extracts were evaporated at 40 ºC to dryness and re-dissolved in DMSO. 
The ethanolic and polysaccharidic (boiling water) extracts were prepared following the 
procedure described by Cheng et al. (2008) with some modification. Polysaccharides 
were extracted from lyophilized mushrooms (~1.5 g) with water at boiling temperature 
(50 ml) for 2 h and agitated (150 rpm; Velp Are magnetic stirrer) and subsequently 
filtered through Whatman No. 4 paper. The residue was then extracted with two more 
portions of boiling water, in a total of 6 h of extraction. The combined extracts were 
lyophilized, and then 95 % ethanol (10 ml) was added and polysaccharides were 
precipitated overnight at 4 ºC. The precipitated polysaccharides were collected after 
centrifugation (Centorion K24OR- 2003 refrigerated centrifuge) at 3100 × g for 40 min 
followed by filtration, and then were lyophilized, resulting in a crude polysaccharidic 
sample. The ethanolic supernatant was evaporated at 40 ºC under reduced pressure 
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(rotary evaporator Büchi R-210), giving the ethanolic extract. The crude polysaccharidic 
samples were re-dissolved in water, while the ethanolic extracts were re-dissolved in 
ethanol for the antioxidant activity assays. For the tumour cell growth screening assays, 
both extracts were re-dissolved in DMSO. The solutions were stored at -20 ºC until 
further use. Final concentration of DMSO showed no interference with the biological 
activity tested. 
 
2.4. Antioxidant activity 
Phenolics determination. For the determination of the content in phenols in the 
ethanolic extracts, the sample (1 ml) was mixed with Folin-Ciocalteu phenol reagent (1 
ml). After 3 min, saturated sodium carbonate solution (1 ml) was added to the mixture 
and adjusted to 10 ml with distilled water. The reaction was kept in the dark for 90 min 
(following Heleno et al., 2010), after which the absorbance was read at 725 nm 
(Analytikijena 200-2004 spectrophotometer). Gallic acid was used to calculate the 
standard curve of absorbance vs. concentration (1×10−5-4×10−4 mol⋅l−1; Y = 
2.8557X−0.0021; R2 = 0.9999) and the results were expressed as mg of gallic acid 
equivalents (GAEs) per g of extract.  
 
DPPH radical-scavenging activity. This methodology was performed using an ELX800 
Microplate Reader (Bio-Tek Instruments, Inc), according to Heleno et al. (2010). The 
reaction mixture in each one of the 96-wells consisted of one of the serial concentrations 
of the extracts (30 μl) and aqueous methanolic solution (80:20 v/v, 270 μl) containing 
DPPH radicals (6×10-5 mol.l-1). The mixture was left to stand for 60 min in the dark. 
The reduction of the DPPH radical was determined by measuring the absorption at 515 
nm. The radical scavenging activity (RSA) was calculated as a percentage of DPPH 
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discolouration using the equation: % RSA = [(ADPPH-AS)/ADPPH] × 100, where AS is the 
absorbance of the solution when the sample extract has been added at a particular level, 
and ADPPH is the absorbance of the DPPH solution. The extract concentration providing 
50 % of radicals scavenging activity (EC50) was calculated from the graph of RSA 
percentage against extract concentration. Trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid) was used as standard. 
 
Reducing power. The serial concentrations of the extracts (0.5 ml) were mixed with 
sodium phosphate buffer (200 mmol.l-1, pH 6.6, 0.5 ml) and potassium ferricyanide (1 
% w/v, 0.5 ml). The mixture was incubated at 50 ºC for 20 min, and trichloroacetic acid 
(10 % w/v, 0.5 ml) was added. The mixture (0.8 ml) was poured in the 48-wells, as also 
deionised water (0.8 ml) and ferric chloride (0.1 % w/v, 0.16 ml), and the absorbance 
was measured at 690 nm in the Microplate Reader described above (Heleno et al., 
2010). The extract concentration providing 0.5 of absorbance (EC50) was calculated 
from the graph of absorbance at 690 nm against extract concentration. Trolox was used 
as standard. 
 
Inhibition of β-carotene bleaching. The antioxidant activity of the extracts was 
evaluated by the β-carotene linoleate model system. A solution of β-carotene was 
prepared by dissolving β-carotene (2 mg) in chloroform (10 ml). Two millilitres of this 
solution were added to a 100 ml round-bottom flask. After the chloroform was removed 
at 40 ºC under vacuum, linoleic acid (40 mg), Tween® 80 emulsifier (400 mg), and 
distilled water (100 ml) were added to the flask and vigorously shaken. Aliquots (4.8 
ml) of this emulsion were transferred into different test tubes containing serial 
concentrations (0.2 ml) of the extracts. The tubes were shaken and incubated at 50 ºC in 
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a water bath (Heleno et al., 2010). As soon as the emulsion was added to each tube, the 
zero time absorbance at 470 nm was measured. A blank, devoid of β-carotene, was used 
for background subtraction. Lipid peroxidation inhibition was calculated using the 
following equation: (β-carotene content after 2 h of assay)/(initial β-carotene content) × 
100. The extract concentration providing 50 % antioxidant activity (EC50) was 
calculated by interpolation from the graph of antioxidant activity percentage against 
extract concentration. Trolox was used as standard.  
 
2.5. Growth inhibition of Tumour Cell Lines  
The effects of the extracts on the growth of human tumour cell lines was evaluated 
according to the procedure adopted in the NCI’s in vitro anticancer drug screening, 
which uses SRB assay to assess cell growth inhibition (Skehan et al., 1990). This 
colorimetric assay estimates cell number indirectly, by staining cellular protein with the 
protein-binding dye SRB. Four human tumour cell lines were used: NCI-H460 (lung 
cancer), MCF-7 (breast cancer), HCT-15 (colon cancer) and AGS (gastric cancer). Cells 
were routinely maintained as adherent cell cultures in RPMI-1640 medium containing 5 
% heat-inactivated FBS at 37 ºC, in a humidified air incubator containing 5 % CO2. 
Each cell line was plated at an appropriate density (5.0 × 103 cells/well for NCI-H460 
and MCF-7, 1.0 × 104 cells/well for HCT-15 and 7.5 × 103 cells/well for AGS) in 96-
well plates and allowed to attach for 24 h. Cells were then treated for 48 h with various 
extract concentrations. Following this incubation period, the adherent cells were fixed 
with 10 % trichloroacetic acid (final concentration), washed with 1 % acetic acid and 
stained with SRB. The bound stain was solubilised with 10 mM Tris and the absorbance 
was measured at 490 nm in a microplate reader (BIORAD 680 model). The 
concentration that inhibited growth in 50 % (GI50) was calculated as described by 
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Monks et al. (1991). The growth inhibitory activity of the extracts was inferred from the 
SRB assay by comparing the absorbance of the wells containing extract-treated cells 
with the absorbance of the wells containing untreated cells, 48 h following treatment 
with the extracts, and subsequently comparing these results with the ones obtained for 
cells that had been fixed at time zero (time at which extracts were added) (Pedro et al., 
2002). 
 
2.6. Statistical analysis 
For each assay 3-6 independent experiments were performed in duplicate. The results 
are expressed as mean values ± standard deviation (SD) or standard error (SE). One-
way analysis of variance (ANOVA) followed by Tukey’s HSD Test was performed with 
the SPSS v.16.0 software. Differences in p values bellow 0.05 were considered 
statistically significant. 
 
3. Results and discussion 
In the present work we tested the whole mushrooms extracts, taking advantage of the 
idea that complex mixture of phytochemicals may have potential additive or synergistic 
effects (Liu, 2004). Three different extracting solvents were used in order to obtain low 
molecular weight compounds such as phenolic antioxidants (methanol and ethanol) and 
high molecular weight compounds such as polysaccharides (boiling water).  
Results show that the ethanolic extracts of Lepista inversa (10.8 mg GAEs/g) and 
Clitocybe alexandri (6.3 mg GAEs/g) have higher phenolic content than the 
corresponding methanolic extracts (Table 1). The phenolic content found in all the 
extracts of L. inversa was significantly (p<0.05) higher than what was found in C. 
alexandri. We hypothesize that this could be related to differences in the lignocelulolitic 
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capacities of the two saprotrophic species, which are well known to vary along the 
fructification process, but this needs further confirmation. Many mushroom species 
have the biosynthetic potential to produce and secrete a wide spectrum of enzymes, both 
saccharifying (cellulases, hemicellulases, xylanases) and oxidative (lignin peroxidases, 
manganese peroxidases and lacases), which enable them to thrive over a range of plant 
wastes. The degraded products are used as their energy source to produce protein rich 
biomass (Periasamy and Natarajan, 2004). In previous studies some of us have reported 
that these mushrooms possess antioxidants other than phenols, such as tocopherols 
(Heleno et al., 2010) and reducing sugars (Heleno et al., 2009).  
All the extracts proved to have free radical scavenging activity and reducing power, but 
to different extent. The antioxidant activity was measured against radical species 
generated in the reaction system, such as DPPH radicals (DPPH scavenging activity 
assay) and linoleate-free radical (β-carotene bleaching inhibition assay), or by the 
reducing effect on Fe3+/ferricyanide complex (reducing power assay). Ethanolic extracts 
gave higher antioxidant activity (lower EC50 values; Table 1) than methanolic extracts, 
which is in agreement with the highest content in phenolics found in the first extracts. 
Nevertheless, it was the polysaccharidic extracts that revealed the most potent 
antioxidant activity in the three assays (EC50 < 2.5 mg/ml; Table 1).  
 
The effects of the mushroom extracts on the growth of four human tumour cell lines 
(NCI-H460, MCF-7, HCT-15 and AGS), represented as the concentrations that were 
able to cause 50 % of cell growth inhibition (GI50), are summarized in Table 2. 
Phenolic (methanolic and ethanolic) and polysaccharidic (boiling water) extracts from 
Clitocybe alexandri and Lepista inversa revealed capacity to inhibit 50 % of the growth 
of all the human tumour cell lines studied, with concentrations lower than 160 µg/ml. C. 
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alexandri was more potent than L. inversa in inhibiting the growth of the four studied 
human tumour cell lines. For C. alexandri, the lower GI50 values were generally 
obtained with the ethanolic extracts, while for L. inversa, methanolic extracts proved to 
be generally more potent, with the exception of the AGS cells (in which the more potent 
extract was the ethanolic). For both mushrooms, the polysaccharidic extract was the less 
potent one. 
The growth inhibitory effect presented by the extracts, as determined by the SRB assay, 
results froma balance between cell proliferation and cell death. However, this assay can 
not infer which effect (cytotoxic or cytostatic) is more prevalent.  Further assays would 
need to be carried out in order to clarify the mechanism of action of these extracts, e.g. 
BrdU (for proliferation) and Annexin V-FITC/PI (for apoptosis). Nonetheless, for the 
ethanolic extract of Clitocybe alexandri, where the % growth (in NCI-H460 cells) at 
high concentrations is lower than that observed at time zero, there is a clear indication 
that this extract is exerting a cytotoxic effect in addition to the cytostatic effect (Figure 
1). 
 
In summary, polysaccharidic extract of Lepista inversa was the most potent as 
antioxidant, while the ethanolic phenolic extract of Clitocybe alexandri was the most 
potent as inhibitor of growth of human tumour cell lines. This interesting growth 
inhibitory activity proves that these mushrooms, particularly the ethanolic extract of 
Clitocybe alexandri, are promising sources of bioactive compounds. Methanolic 
extracts of fresh fruiting bodies of Lepista inversa collected in France were described in 
the literature as having cytotoxic activity against two mouse tumour cell lines, L1210 
(lymphocytic leukemia) and 3LL (Lewis lung carcinoma), and against four human 
tumour cell lines: K-562 (leukemia), U251 (glioma), DU145 (prostate cancer) and 
 
 
 
12
MCF7 (breast cancer) (Bezivin et al., 2002). Clitocine, an exocyclic amino nucleoside 
isolated from this mushroom also revealed growth inhibitory activity against the same 
four tumour cell lines (Fortin et al., 2006). Nevertheless, there are no reports of growth 
inhibitory activity against lung, colon and gastric human cancer cells. To our 
knowledge, this is the first report describing growth inhibitory properties of Clitocybe 
alexandri in human tumour cell lines. Future work will elucidate the mechanism of 
action of these extracts leading to the observed cell growth inhibition. 
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Table 1. Antioxidant activity of the mushroom extracts.  
Species Extracts 
Extraction 
yield (%) 
Phenolics 
(mg GAEs/g) 
DPPH scavenging 
activity 
Reducing 
power 
β-carotene bleaching 
inhibition 
Phenolic (methanolic)a 47.7 ± 5.3 1.5 ± 0.1  28.7 ± 3.2  7.0 ± 0.4  4.5 ± 0.2 
Phenolic (ethanolic) 3.5 ± 0.2 6.3 ± 0.4 10.7 ± 0.8 2.3 ± 0.0 3.7 ± 0.1 
 
Clitocybe alexandri
Polysaccharidic (boiling water) 30.3 ± 2.8 na 2.5 ± 0.0 0.9 ± 0.0 1.2 ± 0.0 
Phenolic (methanolic)a 39.0 ± 1.9 3.6 ± 0.1  10.6 ± 1.1 2.9 ± 0.1  1.1 ± 0.1 
Phenolic (ethanolic) 4.6 ± 0.5 10.8 ± 0.7 9.3 ± 0.5 1.4 ± 0.1 1.5 ± 1.1 
 
Lepista inversa 
 Polysaccharidic (boiling water) 32.2 ± 3.1 na 1.8 ± 0.1 0.7 ± 0.0 0.9 ± 0.1 
Results are expressed as EC50 (concentrations of extracts in mg/ml that cause 50 % of antioxidant activity, unless for reducing power that is 0.5 
of absorbance), and show means ± SE of 3 independent experiments performed in duplicate; na- not analysed; a Heleno et al., 2010. 
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Table 2. Effect of the mushroom extracts on the growth of human tumour cell lines.  
Species Extracts 
NCI-H460 
(lung cancer)
MCF-7 
(breast cancer)
HCT-15  
(colon cancer) 
AGS 
(gastric cancer)
Phenolic (methanolic) 34.8 ± 2.8 34.2 ± 1.4 36.9 ± 3.1 36.1 ± 2.3 
Phenolic (ethanolic) 24.8 ± 2.3 17.9 ± 1.3 21.7 ± 2.3 26.0 ± 1.3 
 
Clitocybe alexandri 
Polysaccharidic (boiling water) 24.5 ± 1.8 46.8 ± 1.6 59.1 ± 0.7 51.7 ± 0.9 
Phenolic (methanolic) 36.3 ± 5.1 45.2 ± 3.1 39.7± 4.6 67.4 ± 5.5 
Phenolic (ethanolic) 118.3± 2.5 79.1 ± 11.8 42.3 ± 4.5 58.5 ± 3.3 
 
Lepista inversa 
 Polysaccharidic (boiling water) 155.0± 3.5 137.4 ± 1.3 77.4 ± 5.5 99.9 ± 7.8 
Results are expressed as GI50 (concentrations of extracts in µg/ml that cause 50 % of 
growth inhibition of human tumour cell lines), and show means ± SE of 3-6 
independent experiments performed in duplicate. 
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Figure 1. Percentage of cell growth of the ethanolic phenolic extract of Clitocybe 
alexandri against four human tumour cell lines (breast, MCF7; lung, NCI-H460; colon, 
HCT-15; gastric, AGS) compared to control. Results are the mean ± SD of at least three 
independent experiments, performed in duplicate. 
 
 
